Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onivyde-based chemotherapy vs nab-paclitaxel + gemcitabine in first-line metastatic pancreatic adenocarcinoma
2024-518303-21-00Phase 3Completed
- Sponsor
- Ipsen
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Onivyde + oxaliplatin + 5-fluorouracil/leucovorin with Abraxane + gemcitabine (2 arms). Primary endpoint: Overall survival. Started Oct 2024; status: completed.
02
Drugs
irinotecannab-paclitaxelgemcitabineoxaliplatinfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-518303-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518303-21-00.